高级检索
当前位置: 首页 > 详情页

NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, Dept Hepatobiliary Oncol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China; [2]Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Hlth Sci Ctr, Beijing 100191, Peoples R China; [3]Peking Univ, Hepatopancreatobiliary Surg Dept 1, Key Lab Carcinogenesis & Translat Res, Minist Educ,Sch Oncol,Beijing Canc Hosp & Inst, 52 Fucheng Rd, Beijing 100142, Peoples R China; [4]Peking Univ, Sch Basic Med Sci, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China
出处:
ISSN:

关键词: NAT10 Hepatocellular carcinoma Prognosis Mutant p53 Stability

摘要:
Background: N-acetyltransferase 10 (NAT10) is a histone acetyltransferase which is involved in a wide range of cellular processes. Recent evidences indicate that NAT10 is involved in the development of human cancers. Previous study showed that NAT10 acetylates the tumor suppressor p53 and regulates p53 activation. As Tp53 gene is frequently mutated in hepatocellular carcinoma (HCC) and associates with the occurrence and development of HCC, the relationship between NAT10 and HCC was investigated in this study. Methods: Immunohistochemistry (IHC) and western blot analysis were performed to evaluate the NAT10 expression in HCC. Immunoprecipitation experiments were performed to verify the interaction of NAT10 with mutant p53 and Mdm2. RNA interference and Western blot were applied to determine the effect of NAT10 on mutant p53. Cell growth curve was used to examine the effect of NAT10 on HCC cell proliferation. Results: NAT10 was upregulated in HCC and increased NAT10 expression was correlated with poor overall survival of the patients. NAT10 protein levels were significantly correlated with p53 levels in human HCC tissues. Furthermore, NAT10 increased mutant p53 levels by counteracting Mdm2 action in HCC cells and promoted proliferation in cells carrying p53 mutation. Conclusion: Increased NAT10 expression levels are associated with shortened patient survival and correlated with mutant p53 levels. NAT10 upregulates mutant p53 level and might enhance its tumorigenic activity. Hence, we propose that NAT10 is a potential prognostic and therapeutic candidate for p53-mutated HCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Dept Hepatobiliary Oncol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China;
通讯作者:
通讯机构: [3]Peking Univ, Hepatopancreatobiliary Surg Dept 1, Key Lab Carcinogenesis & Translat Res, Minist Educ,Sch Oncol,Beijing Canc Hosp & Inst, 52 Fucheng Rd, Beijing 100142, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号